TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial

Andrea Necchi, Félix Guerrero‐Ramos, Paul L. Crispen, Bernardo Herrera‐Imbroda, Rohan Garje, Thomas Powles, Cheri L. Peyton, Benjamin Pradere, Ja Hyeon Ku, Neal D. Shore, Martin Bögemann, Mark A. Preston, Évanguelos Xylinas, Cristina Sánchez de Llano, Mohamad Hasan, Hind Stitou, Sumeet Bhanvadia, Hussein Sweiti, Sarah P. Psutka